Dr. Jamese J. Hilliard has been in her profession for 25 years, and is working with Janssen Pharmaceutical Research & Development (a Johnson & Johnson company) as Principal Scientist, PreClinical Models Leader in the Infectious Disease/Microbiome Department.
Having always had a natural interested in science since she was a child, it was no surprise she went all the way in her profession, earning her Doctorate from Rutgers University in NJ in Microbiology/Molecular Genetics, 1993. She has done extensive research in her field, but is now focusing on the clinical aspects of research. She is part of the American Society for Microbiology.
An experienced infectious Disease Pre-clinical Research Biologist with extensive experience leading and conducting pre-clinical models of inflammation/infectious disease in an AAALAC accredited facility, she holds a distinctive combination of leadership, collaboration and technical strengths generate scientific insight, process improvement and cost savings. Some of her expertise includes due diligence evaluations for licensing and acquisition opportunities of therapeutic biologicals, antibodies, small molecules and antibiotics.
Dr. Hilliard is always willing to try new things and learn something new, and is most proud of work she did getting antibiotics to patients. She is looking forward to networking and connecting with other like-minded professionals, and to gaining the recognition and credibility of being a member.
Worldwide Association of Female Professionals Member, Dr. Jamese J. Hilliard, can be found on the Association Directory, where she is looking forward to networking with you.
Program Management – Designed and led pre-clinical teams leading to adoption of shorter courses of treatment.
Pre-Clinical Technical Advising – Shifted focus toward immunology parameters and utility of combination therapies.
Infectious Disease Research – Created in vivo models that better evaluated combination therapy and host response.
- Awarded Medimmune ‘Science Day Top 10 Posters’ -“Evaluation of anti-Alpha Toxin mAb and Vancomycin combination therapy in a Murine MRSA Pneumonia Model”.
- Awarded the prestigious MedImmune ‘Patent of the Year’ – 2014 for the “Treatment of Polybacterial Infections”.
- Awarded Paper of the Year -“A multifunctional bispecific antibody protects against Pseudomonas aeruginosa”.